# FDA recall D-0151-2026

> **Teva Pharmaceuticals USA, Inc** · Class II · drug recall initiated 2025-10-13.

## Product

Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx only, manufactured in Canada by: Teva Canada Limited, Toronto, Canada M1B 2K9; Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054 NDC 0093-2277-7.

## Reason for recall

Subpotent drug; Clavulanate Potassium component

## Distribution

Distributed in three (3) States: MS, OH, CA.

## Key facts

- **Recall number:** D-0151-2026
- **Recalling firm:** Teva Pharmaceuticals USA, Inc
- **Classification:** Class II
- **Product type:** drug
- **Status:** Ongoing
- **Initiation date:** 2025-10-13
- **Report date:** 2025-11-12

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Parsippany, NJ, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0151-2026

## Citation

> AI Analytics. FDA recall D-0151-2026. Retrieved 2026-07-26 from https://api.ai-analytics.org/recall/D-0151-2026. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*